Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Donafenib”

54 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 54 results

Testing effectiveness (Phase 2)Looking for participantsNCT06812039
What this trial is testing

HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence

Who this might be right for
Hepato Cellular Carcinoma (HCC)
Fudan University 165
Testing effectiveness (Phase 2)Study completedNCT04962958
What this trial is testing

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

Who this might be right for
CarcinomaCarcinoma, HepatocellularLiver Neoplasms+6 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07353827
What this trial is testing

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

Who this might be right for
Intrahepatic Cholangiocarcinoma (Icc)Hepatic Arterial Infusion Chemotherapy
Sun Yat-sen University 36
Testing effectiveness (Phase 2)UnknownNCT05545124
What this trial is testing

Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

Who this might be right for
Hepatocellular Carcinoma
Henan Cancer Hospital 32
Testing effectiveness (Phase 2)Looking for participantsNCT05668884
What this trial is testing

GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma

Who this might be right for
Biliary Tract Carcinoma
Fudan University 93
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07557914
What this trial is testing

Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes

Who this might be right for
HCC - Hepatocellular CarcinomaDiabetes
Haibo Shao 32
Testing effectiveness (Phase 2)Looking for participantsNCT06646198
What this trial is testing

TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension

Who this might be right for
Hepatocellular Carcinoma with PVTT
Fei Gao 40
Not applicableLooking for participantsNCT06581315
What this trial is testing

Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma

Who this might be right for
Hepatocellular CarcinomaAdjuvant Therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 204
Testing effectiveness (Phase 2)Study completedNCT02229071
What this trial is testing

Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma

Who this might be right for
HCC
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 106
Testing effectiveness (Phase 2)Ended earlyNCT04612712
What this trial is testing

Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors

Who this might be right for
Advanced Gastrointestinal Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 15
Testing effectiveness (Phase 2)Looking for participantsNCT06498622
What this trial is testing

Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab

Who this might be right for
Hepatocellular Carcinoma
Anhui Provincial Hospital 45
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07157306
What this trial is testing

Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital 35
Testing effectiveness (Phase 2)Looking for participantsNCT06244225
What this trial is testing

HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 38
Testing effectiveness (Phase 2)Study completedNCT05162352
What this trial is testing

Donafenib Plus Sintilimab for Advanced HCC

Who this might be right for
Hepatocellular Carcinoma
Second Affiliated Hospital of Guangzhou Medical University 30
Testing effectiveness (Phase 2)Study completedNCT02489916
What this trial is testing

Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 47
Post-approval studies (Phase 4)UnknownNCT05022628
What this trial is testing

Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis

Who this might be right for
HCCChemotherapy Effect
Anhui Provincial Hospital 30
Testing effectiveness (Phase 2)UnknownNCT05161143
What this trial is testing

Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Peking Union Medical College Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07230314
What this trial is testing

Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Treated With Donafenib

Who this might be right for
Unresectable Hepatocellular Carcinoma
Jinling Hospital, China 34
Not applicableUnknownNCT05638438
What this trial is testing

Efficacy and Safety of Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC: A Retrospective Real-world Study

Who this might be right for
Hepatocellular Carcinoma Non-resectable
Zhujiang Hospital 100
Not applicableUnknownNCT05205629
What this trial is testing

A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC

Who this might be right for
Hepatocellular CarcinomaDonafenib
Shanghai Zhongshan Hospital 150
Next Page